BioCryst (BCRX) Stock Up on Q4 Orladeyo Preliminary Sales

Published on January 11, 2022

BioCryst's (BCRX) sole marketable drug, Orladeyo reports preliminary sales for the fourth quarter. The company also provides its revenue guidance for 2022.

Continue reading on website
Other news

Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

January 11, 2022
The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

5 Top-Ranked ETFs to Add to Your Portfolio for 2022

January 11, 2022
We have highlighted some ETFs from different zones that are poised to outperform in 2022 given the current trends.